Ovarian cancer accounts for 4% of all cancers in women and is the leading cause of death
from gynaecologic malignancies. Because early-stage ovarian cancer is generally …

Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often
characterized by administration of multiple, sequential active agents, each of which may or …

BACKGROUND: Despite improvements in the treatment of ovarian cancer, most patients
develop recurrent disease within 3 years of diagnosis. There is no agreed second-line …

OBJECTIVE: To determine the impact on progression-free survival (PFS) and overall
survival (OS) of a programmatic change in surgical approach to advanced epithelial ovarian …

The research team of Dr. Monroe E. Wall and Dr. Mansukh C. Wani of Research Triangle
Institute discovered two first-in-class life-saving chemotherapeutic agents. Camptothecin …

Purpose Limited information is available regarding the influence of the duration of a prior
response on the length of a subsequent response to platinum chemotherapy in recurrent …

Multimodal nanotherapeutic cancer treatments are widely studied but are often limited by
their costly and complex syntheses that are not easily scaled up. Herein, a simple …

Purpose: Carboplatin-associated hypersensitivity is increasingly recognized as a potentially
serious toxicity when this agent is administered for more than six total cycles. Patients and …

We undertook a systematic review of the pre-clinical and clinical literature for studies
investigating the relationship between platinum and taxane resistance. Medline was …

The management and the outcome of peritoneal metastases or recurrence from epithelial
ovarian cancer are presented. The biology and the diagnostic tools of EOC peritoneal …